• In April 2026, NovoCure reported first-quarter 2026 results showing sales of US$174.06 million and a net loss of US$71.14 million, while also updating its full-year 2026 net revenue outlook to US$690 million–US$710 million from US$675 million–US$705 million.
• The combination of stronger quarterly sales and a higher full-year revenue range gives investors fresh insight into how management views current demand for its tumor treating fields devices.
• We’ll now examine how NovoCure’s higher 2026 revenue guidance reshapes the earlier investment narrative around growth, risk, and profitability.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.

NovoCure Investment Narrative Recap

To own NovoCure, you have to believe tumor treating fields can become a meaningful cancer therapy across multiple indications while eventually supporting a path toward profitability. The latest Q1 2026 results and slightly higher revenue guidance refine, but do not radically change, the near term picture. Higher expected 2026 sales help the growth side of the story, but the wider net loss underlines that cash burn and timing to sustainable earnings remain the central risk right now.

The most relevant recent announcement here is NovoCure’s decision on April 30, 2026 to raise full year 2026 net revenue guidance to US$690 million to US$710 million from US$675 million to US$705 million. That move, paired with Q1 sales of US$174.06 million and a larger quarterly net loss, directly informs how you might weigh growth catalysts like new indications and reimbursement wins against the ongoing pressure from negative earnings and persistent operating losses.

Yet behind this improved revenue outlook, there is still the question of how long NovoCure can sustain growing losses before...

NovoCure's narrative projects $915.6 million revenue and $119.8 million earnings by 2029.

Uncover how NovoCure's forecasts yield a $26.07 fair value, a 44% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$930.1 million by 2028 and earnings around US$114.6 million, which is a far more bullish take than the consensus view and highlights how differently you might weigh upside from faster regulatory approvals versus the risk that reimbursement and adoption never fully catch up to rising costs.

Explore 4 other fair value estimates on NovoCure - why the stock might be worth just $26.07!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NovoCure research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free NovoCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NovoCure's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.